CUSIP 68236X100 · who reports it, how much, and how much it matters to them
18 of the 720 hedge fund managers we track reported shares of Starling Oncology, Inc. (Nasdaq: STLN) on Form 13F for 30 June 2026. Between them they reported USD 46m. The largest position belongs to Wexford Capital, at USD 9.3m. The manager with the most riding on it is Fourworld Capital Management, where it is 2.5% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Wexford Capital8 funds on PPLI.com | USD 9.3m | 1.2% |
| 2 | Renaissance Technologies13 funds on PPLI.com | USD 7.4m | 0.0% |
| 3 | Marshall Wace LLP84 funds on PPLI.com | USD 6.6m | 0.0% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 4.9m | 0.0% |
| 5 | Two Sigma Investments35 funds on PPLI.com | USD 3.6m | 0.0% |
| 6 | Fourworld Capital Management8 funds on PPLI.com | USD 2.7m | 2.5% |
| 7 | Manatuck Hill Partners6 funds on PPLI.com | USD 2.4m | 0.8% |
| 8 | Walleye Capital8 funds on PPLI.com | USD 2.4m | 0.0% |
| 9 | Formula Growth6 funds on PPLI.com | USD 1.6m | 0.6% |
| 10 | Mount Lucas Management2 funds on PPLI.com | USD 1.4m | 0.5% |
| 11 | Boothbay Fund Management2 funds on PPLI.com | USD 1.3m | 0.0% |
| 12 | Panoramic Capital4 funds on PPLI.com | USD 543,000 | 0.2% |
| 13 | Millennium Management6 funds on PPLI.com | USD 526,000 | 0.0% |
| 14 | Squarepoint Ops7 funds on PPLI.com | USD 396,000 | 0.0% |
| 15 | Entrypoint Capital1 fund on PPLI.com | USD 244,000 | 0.1% |
| 16 | Exoduspoint Capital Management7 funds on PPLI.com | USD 183,000 | 0.0% |
| 17 | Engineers Gate Manager1 fund on PPLI.com | USD 67,017 | 0.0% |
| 18 | The Quarry1 fund on PPLI.com | USD 842 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fourworld Capital Management | USD 2.7m | 2.5% |
| 2 | Wexford Capital | USD 9.3m | 1.2% |
| 3 | Manatuck Hill Partners | USD 2.4m | 0.8% |
| 4 | Formula Growth | USD 1.6m | 0.6% |
| 5 | Mount Lucas Management | USD 1.4m | 0.5% |
| 6 | Panoramic Capital | USD 543,000 | 0.2% |
| 7 | Entrypoint Capital | USD 244,000 | 0.1% |
| 8 | Boothbay Fund Management | USD 1.3m | 0.0% |
| 9 | Renaissance Technologies | USD 7.4m | 0.0% |
| 10 | Walleye Capital | USD 2.4m | 0.0% |
Starling Oncology, Inc. trades under the symbol STLN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 68236X100.
18 of the 720 hedge fund managers PPLI.com tracks reported Starling Oncology, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Wexford Capital (USD 9.3m), Renaissance Technologies (USD 7.4m), Marshall Wace LLP (USD 6.6m), Citadel Advisors (USD 4.9m) and Two Sigma Investments (USD 3.6m).
18 managers in our coverage reported it, and between them they run 231 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Fourworld Capital Management, where the position was 2.5% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Starling Oncology, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.